Time burden, time spent at home, and persistence with azacitidine or decitabine plus venetoclax in newly diagnosed acute myeloid leukemia in the United States
By downloading this material, you acknowledge that this action may be considered a transfer of value and will be reported by Taiho Oncology, Inc. in accordance with applicable Transparency and Sunshine Act requirements.